224 related articles for article (PubMed ID: 33857789)
1. Efficacy and safety of apixaban for primary prevention in gastrointestinal cancers: A post-hoc analysis of the AVERT trial.
Ladha D; Mallick R; Wang TF; Caiano L; Wells PS; Carrier M
Thromb Res; 2021 Jun; 202():151-154. PubMed ID: 33857789
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of apixaban for primary prevention of thromboembolism in patients with cancer and a central venous catheter: A subgroup analysis of the AVERT Trial.
Brandt W; Brown C; Wang TF; Tagalakis V; Shivakumar S; Ciuffini LA; Mallick R; Wells PS; Carrier M
Thromb Res; 2022 Aug; 216():8-10. PubMed ID: 35660801
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of apixaban thromboprophylaxis in ambulatory cancer patients according to renal function: A subgroup analysis of the AVERT trial.
Wang TF; Mallick R; Carrier M; Wells PS
Thromb Res; 2022 Mar; 211():85-87. PubMed ID: 35124234
[TBL] [Abstract][Full Text] [Related]
4. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer.
Carrier M; Abou-Nassar K; Mallick R; Tagalakis V; Shivakumar S; Schattner A; Kuruvilla P; Hill D; Spadafora S; Marquis K; Trinkaus M; Tomiak A; Lee AYY; Gross PL; Lazo-Langner A; El-Maraghi R; Goss G; Le Gal G; Stewart D; Ramsay T; Rodger M; Witham D; Wells PS;
N Engl J Med; 2019 Feb; 380(8):711-719. PubMed ID: 30511879
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of apixaban thromboprophylaxis in cancer patients with metastatic disease: A post-hoc analysis of the AVERT trial.
Knoll W; Mallick R; Wells PS; Carrier M
Thromb Res; 2021 Jan; 197():13-15. PubMed ID: 33160115
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of primary prevention of venous thromboembolism among subgroups of cancer patients undergoing chemotherapy: A post- hoc analysis of the AVERT trial.
Nayak AL; Zahrai A; Mallick R; Wang TF; Delluc A; Castellucci LA; Carrier M; Wells PS
Thromb Res; 2021 Dec; 208():79-82. PubMed ID: 34742140
[TBL] [Abstract][Full Text] [Related]
7. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Goldhaber SZ; Leizorovicz A; Kakkar AK; Haas SK; Merli G; Knabb RM; Weitz JI;
N Engl J Med; 2011 Dec; 365(23):2167-77. PubMed ID: 22077144
[TBL] [Abstract][Full Text] [Related]
8. Thromboprophylaxis for patients with newly diagnosed vs. recurrent cancers: a post-hoc analysis of the avert trial.
Zhang J; Atalla M; Mallick R; Wells PS; Carrier M
J Thromb Thrombolysis; 2021 Apr; 51(3):720-724. PubMed ID: 33079379
[TBL] [Abstract][Full Text] [Related]
9. Oral apixaban for the treatment of acute venous thromboembolism.
Agnelli G; Buller HR; Cohen A; Curto M; Gallus AS; Johnson M; Masiukiewicz U; Pak R; Thompson J; Raskob GE; Weitz JI;
N Engl J Med; 2013 Aug; 369(9):799-808. PubMed ID: 23808982
[TBL] [Abstract][Full Text] [Related]
10. Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: Rational and design of the AVERT trial.
Kimpton M; Wells PS; Carrier M
Thromb Res; 2018 Apr; 164 Suppl 1():S124-S129. PubMed ID: 29703470
[TBL] [Abstract][Full Text] [Related]
11. Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: Insights from the AVERT trial.
Potere N; Di Nisio M; Porreca E; Wang TF; Tagalakis V; Shivakumar S; Delluc A; Mallick R; Wells PS; Carrier M
Thromb Res; 2023 Jun; 226():82-85. PubMed ID: 37121015
[TBL] [Abstract][Full Text] [Related]
12. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
Agnelli G; Becattini C; Meyer G; Muñoz A; Huisman MV; Connors JM; Cohen A; Bauersachs R; Brenner B; Torbicki A; Sueiro MR; Lambert C; Gussoni G; Campanini M; Fontanella A; Vescovo G; Verso M;
N Engl J Med; 2020 Apr; 382(17):1599-1607. PubMed ID: 32223112
[TBL] [Abstract][Full Text] [Related]
13. Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial.
O'Brien SH; Rodriguez V; Lew G; Newburger JW; Schultz CL; Orgel E; Derr K; Ranalli MA; Esbenshade AJ; Hochberg J; Kang HJ; Dinikina Y; Mills D; Donovan M; Dyme JL; Favatella NA; Mitchell LG;
Lancet Haematol; 2024 Jan; 11(1):e27-e37. PubMed ID: 37980924
[TBL] [Abstract][Full Text] [Related]
14. D-Dimer Enhances Risk-Targeted Thromboprophylaxis in Ambulatory Patients with Cancer.
Kumar V; Shaw JR; Key NS; Ilich A; Mallick R; Wells PS; Carrier M
Oncologist; 2020 Dec; 25(12):1075-1083. PubMed ID: 32969580
[TBL] [Abstract][Full Text] [Related]
15. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.
Lassen MR; Raskob GE; Gallus A; Pineo G; Chen D; Hornick P;
Lancet; 2010 Mar; 375(9717):807-15. PubMed ID: 20206776
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial.
Guntupalli SR; Brennecke A; Behbakht K; Tayebnejad A; Breed CA; Babayan LM; Cheng G; Ramzan AA; Wheeler LJ; Corr BR; Lefkowits C; Sheeder J; Matsuo K; Flink D
JAMA Netw Open; 2020 Jun; 3(6):e207410. PubMed ID: 32589230
[TBL] [Abstract][Full Text] [Related]
17. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
McBane Ii R; Loprinzi CL; Ashrani A; Perez-Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Le-Rademacher JG; Wysokinski WE
Thromb Haemost; 2017 Oct; 117(10):1952-1961. PubMed ID: 28837207
[TBL] [Abstract][Full Text] [Related]
18. Apixaban for extended treatment of venous thromboembolism.
Agnelli G; Buller HR; Cohen A; Curto M; Gallus AS; Johnson M; Porcari A; Raskob GE; Weitz JI;
N Engl J Med; 2013 Feb; 368(8):699-708. PubMed ID: 23216615
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis.
Dawwas GK; Brown J; Dietrich E; Park H
Lancet Haematol; 2019 Jan; 6(1):e20-e28. PubMed ID: 30558988
[TBL] [Abstract][Full Text] [Related]
20. Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism.
Hannevik TL; Brekke J; Enden T; Frøen H; Garresori H; Jacobsen EM; Paulsen PQ; Porojnicu AC; Ree AH; Torfoss D; Velle EO; Wik HS; Ghanima W; Sandset PM; Dahm AEA
Thromb Res; 2020 Dec; 196():238-244. PubMed ID: 32919178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
